Corvus Pharma Com (CRVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -7,873 | -41,307 | -31,491 | -16,660 | -8,297 |
| Depreciation Amortization | -207 | 197 | 285 | 274 | 142 |
| Accounts receivable | 159 | -81 | 4 | 134 | 134 |
| Accounts payable and accrued liabilities | -569 | 411 | 2,662 | 834 | 624 |
| Other Working Capital | -2,254 | 1,412 | 4,291 | -212 | -49 |
| Other Operating Activity | 2,633 | 12,345 | 4,773 | 3,083 | 1,022 |
| Operating Cash Flow | $-8,111 | $-27,023 | $-19,476 | $-12,547 | $-6,424 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 4,636 | -23,029 | -19,125 | -22,430 | -25,574 |
| PPE Investments | -34 | -247 | -269 | -4 | N/A |
| Investing Cash Flow | $4,602 | $-23,276 | $-19,394 | $-22,434 | $-25,574 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 4 | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $4 | $N/A | $N/A | $N/A | $N/A |
| Beginning Cash Position | 13,159 | 63,458 | 63,458 | 63,458 | 63,458 |
| End Cash Position | 9,654 | 13,159 | 24,588 | 28,477 | 31,460 |
| Net Cash Flow | $-3,505 | $-50,299 | $-38,870 | $-34,981 | $-31,998 |
| Free Cash Flow | |||||
| Operating Cash Flow | -8,111 | -27,023 | -19,476 | -12,547 | -6,424 |
| Capital Expenditure | -34 | -269 | -269 | -4 | N/A |
| Free Cash Flow | -8,145 | -27,292 | -19,745 | -12,551 | -6,424 |